Ugandan authorities launched a clinical trial of a vaccine against the Sudan strain of Ebola that has killed one nurse in the ...

Valneva’s chikungunya vaccine Ixchiq has been greenlit by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) ...

The Vaccine and Infectious Disease Organization out of the University of Saskatchewan has received a $24 million grant to aid ...

Moderna is developing an mRNA-based vaccine for norovirus, now in Phase 3 trials, with hopes of approval by 2026 to combat the highly contagious stomach virus.

Norovirus cases are significantly increasing in the US and Canada. Moderna is developing an mRNA-based vaccine, currently in ...

Ugandan officials initiated a clinical trial on Monday for a vaccine targeting the Sudan strain of Ebola, which has resulted in one fatality since the outbreak was declared last week.

Nearly two years into the COVID-19 pandemic, Canada is ramping up its vaccine program in an effort to deliver booster doses to eligible Canadians. A booster shot is an additional dose of a COVID ...

Medpace demonstrates strong financial performance and growth in the CRO market, despite facing challenges in the short term.

This would reverse progress toward curbing drug shortages. AstraZeneca scrapped plans to invest $558.3 million in its vaccine ...

Robert F. Kennedy's nomination will put Republican lawmakers' loyalty to the test, as the former Democrat holds a range of ...

Dr. Theresa Tam says while international travel has been blamed for the initial outbreaks, recent infections were among ...

H.C. Wainwright reaffirmed its Buy rating and $18.00 price target for Valneva (EPA:VLS) SE (NASDAQ:VALN) shares, following the recent approval of the company's Ixchiq vaccine in the United Kingdom ...